| __timestamp | Amphastar Pharmaceuticals, Inc. | Axsome Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 1392830 |
| Thursday, January 1, 2015 | 46974000 | 2419289 |
| Friday, January 1, 2016 | 47298000 | 6343648 |
| Sunday, January 1, 2017 | 50918000 | 7206691 |
| Monday, January 1, 2018 | 58044000 | 9351522 |
| Tuesday, January 1, 2019 | 63109000 | 13598030 |
| Wednesday, January 1, 2020 | 65157000 | 28896749 |
| Friday, January 1, 2021 | 68920000 | 66646205 |
| Saturday, January 1, 2022 | 66592000 | 159253661 |
| Sunday, January 1, 2023 | 80393000 | 323123000 |
| Monday, January 1, 2024 | 411359000 |
In pursuit of knowledge
In the competitive landscape of pharmaceuticals, understanding the financial strategies of companies can offer valuable insights. Over the past decade, Amphastar Pharmaceuticals, Inc. and Axsome Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amphastar's SG&A expenses grew steadily, peaking at approximately 80 million in 2023, marking a 99% increase from 2014. In contrast, Axsome's expenses skyrocketed, with a staggering 23,000% increase, reaching over 320 million in 2023. This dramatic rise reflects Axsome's aggressive expansion and investment in its operations. The data highlights the contrasting financial strategies: Amphastar's steady growth versus Axsome's rapid scaling. Such insights are crucial for investors and industry analysts aiming to understand the financial health and strategic direction of these companies.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Selling, General, and Administrative Costs: argenx SE vs Amphastar Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Biogen Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Amphastar Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. or Verona Pharma plc: Who Manages SG&A Costs Better?
Axsome Therapeutics, Inc. or Perrigo Company plc: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Axsome Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Axsome Therapeutics, Inc. and Novavax, Inc.
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.